Drug profile
Pomalidomide
GenericRadar assessment
Patent Radar Assessment
Grade B3
United States · 2030 Radar
Verification
HIGH
Why not A?
Not Grade A: the prominent 2030 Orange Book patents US10555939 and US9993467 are flagged Drug Product, not Drug Substance. A separate DS/DP patent US8828427 expires in 2031, so the 2030 event cannot be treated as the core API patent cliff.
Core Patent Expiry
2031-06-21
2030 Target Event
US10555939
Drug Product · 2030-05-19
Core API Event?
No
Later Blocking Patents
Yes. US8828427 is a DS/DP patent expiring 2031-06-21, with pediatric extension into late 2031.
Generic Entry Assessment
2030 is relevant for product/formulation strategy, but API sourcing and final launch timing must account for the later Drug Substance patent.
Patent landscape
| Country | Patent no. | Type | Expiry | Status | Verified | Opportunity |
|---|---|---|---|---|---|---|
| United States | US10555939 | Drug Product | 2030-05-19 | Protected | Yes | 43 |
API sourcing
Regulatory filing labels distinguish verified/listed records from records that have not yet been verified. “Not verified” does not mean that a filing does not exist.
| API | Manufacturer | Country | US DMF | KDMF | Japan MF | CEP | EU GMP | Status |
|---|---|---|---|---|---|---|---|---|
| Pomalidomide | No supplier linked | — | — | — | — | Not verified | — |